Early use of gemfibrozil in patients with non ST elevation acute coronary syndrome. Changes of markers of inflammation and von willebrand factor

Kardiologiya

Volumn 46, Issue 6, 2006, Pages 37-42

  Vaulin, N A ^a   Pokrovskaya, E V ^a   Deev, A D ^a   Gratsiansky, N A ^a  

^a FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

Author keywords

Acute coronary syndrome; C reactive protein; CD40 ligand; Fibrates; Gemfibrozil; Inflammation, markers

Indexed keywords

ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; GEMFIBROZIL; VON WILLEBRAND FACTOR;

ACUTE DISEASE; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLAMMATION; MALE; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYNDROME; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; CORONARY DISEASE; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; INFLAMMATION; MALE; SEVERITY OF ILLNESS INDEX; SYNDROME; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 33748122382     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.
2. Azar R.R., Rinfret S., Theroux P. et al. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000;21:2026-2032.
3. Consilium Medicum 2004;12:918-925. www.athero.ru\rofecox-debacle.htm
4. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes The MIRACL Study: A Randomized Controlled Trial. JAMA 2001;285:1711-1718.
5. Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
6. de Lemos J.A., Blazing M.A., Wiviott S.D. et al. for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316.
7. Martin G., Duez H., Blanquart C. et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001;107:1423-1432.
8. Staels B., Dallongeville J., Auwerx J. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093.
9. Rubins H.B., Robins S.J., Collins D.C. et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
10. Wood D.A., De Backer G., Faergeman O. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-1503.
11. Vishnevetsky D., Kiyanista V.A., Gandhi P.J. CD40 ligand: A novel target in the fight against cardiovascular disease. Ann Pharmacother 2004;38:1500-1508.
12. Heeshen C., Dimmeler S., Hamm C.W. et al. for the CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Eng J Med 2003;348:1104-1111.
13. Montalescot G., Philippe F., Ankri A. et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation 1998;98:294-299.